ABSI
Absci Corp
$6.55
+2.34%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders7 funds
Inst. Value$121.4M
Inst. Activity3 buys / 0 sells
Insider Activity3B / 2S
Insider Net $$503.2K
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·CIK 0001672688·Prev Close $6.40
Recent Activity
Jun 8, 2026
short_volume
Short Volume: ABSI — 63.0% short (0.8M / 1.3M)
Short: 806,968 | Exempt: 40,903 | TRF Vol: 1,280,288 | Short Ratio: 63.0% | Off-exchange volume (dar
Jun 4, 2026
Insider
Szela Mary T sold 39,800 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Szela Mary T sold 10,100 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Pangalos Menelas N sold 10,100 shares
Director @ $0.00 ($0.00)
Apr 23, 2026
SEC
Absci Corporation announced it will report Q1 2026 financial and operating results on May 7, 2026, along with business u
PRESS-RELEASE — Impact 3/10
Apr 22, 2026
SEC
Absci Corp has filed definitive additional proxy materials (DEFA14A) related to a shareholder vote, likely on director e
DEFA14A — Impact 2/10
Inst.
MORGAN STANLEY — ADD
1,478,838 shares ($5.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
1,418,416 shares ($5.0M)
Price Targets
$9.11
+33.4% upside
Strong Buy
Current $6.83
Low $4.10
Median $9.50
High $12.00
10 analysts
$4.10
$12.00
Analyst Ratings
4Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | INITIATE | Outperform |
| May 28, 2026 | BTIG | INITIATE | Buy |
| May 8, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Mar 30, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 25, 2026 | Needham | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +2.5% | $-0.22 — $-0.16 | 17% YoY | 9 |
| Next Q | $-0.20 ▼ -4.0% | $-0.23 — $-0.14 | -2% YoY | 9 |
| Current FY | $-0.77 ▲ +3.6% | $-0.87 — $-0.59 | 12% YoY | 11 |
| Next FY | $-0.64 ▼ -2.8% | $-0.87 — $-0.23 | 17% YoY | 11 |
Latest Reports
NEUTRAL
PRESS-RELEASE
3/10
Absci Corporation announced it will report Q1 2026 financial and operating results on May 7, 2026, along with business u
Apr 23, 2026
NEUTRAL
DEFA14A
2/10
Absci Corp has filed definitive additional proxy materials (DEFA14A) related to a shareholder vote, likely on director e
Apr 22, 2026
NEUTRAL
Press
4/10
Absci Corporation announced the successful dosing of the first three cohorts in the SAD portion of its ABS-201™ HEADLINE
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $78.1M | ADD |
| VANGUARD GROUP INC | $27.6M | ADD |
| MORGAN STANLEY | $5.2M | ADD |
| TWO SIGMA INVESTMENTS, LP | $5.0M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Szela Mary | A | $0.00 |
| Jun 4, 2026 | Szela Mary | A | $0.00 |
| Jun 4, 2026 | Pangalos Menelas | A | $0.00 |
| Jun 4, 2026 | Pangalos Menelas | A | $0.00 |
| Jun 4, 2026 | VAN HOUTEN | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $121.4M total value (34,774,306 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 22,382,002 | $78.1M | 64.4% | ADD +36.1% |
| 2 | VANGUARD GROUP INC | 7,910,205 | $27.6M | 22.7% | ADD +37.6% |
| 3 | MORGAN STANLEY | 1,478,838 | $5.2M | 4.3% | ADD +52.5% |
| 4 | TWO SIGMA INVESTMENTS, LP | 1,418,416 | $5.0M | 4.1% | DOUBLED +1015.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,115,373 | $3.9M | 3.2% | ADD +33.1% |
| 6 | BANK OF AMERICA CORP /DE/ | 313,832 | $1.1M | 0.9% | NEAR_EXIT -85.2% |
| 7 | WELLS FARGO & COMPANY/MN | 155,640 | $543.2K | 0.4% | ADD +71.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 969,868 | 1,478,838 | +52.5% | $5.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 127,155 | 1,418,416 | +1015.5% | $5.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 90,622 | 155,640 | +71.7% | $543.2K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 822,675 | 1,094,756 | +33.1% | $3.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,867,669 | 275,626 | -85.2% | $837.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 580,438 | 127,155 | -78.1% | $386.6K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 66,881 | 90,622 | +35.5% | $275.5K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 4,687,673 | 6,451,582 | +37.6% | $16.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 451,099 | 580,438 | +28.7% | $1.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 48,537 | 66,881 | +37.8% | $171.9K | 2025-Q2 |
| FMR LLC | ADD | 13,512,945 | 18,386,849 | +36.1% | $46.2M | 2025-Q1 |
| UBS Group AG | DOUBLED | 714,145 | 2,063,207 | +188.9% | $5.2M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 462,147 | 1,457,835 | +215.4% | $3.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 583,431 | 1,285,279 | +120.3% | $3.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 899,648 | 451,099 | -49.9% | $1.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 46,634 | 714,145 | +1431.4% | $1.9M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 121,100 | 583,431 | +381.8% | $1.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 30,979 | 44,027 | +42.1% | $115.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 697,849 | — | $2.7M | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 133,176 | 501,706 | +276.7% | $1.9M | 2024-Q3 |
10 unique insiders with 5 transactions. Net insider value: $503.2K ($635.5K bought, $132.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Szela Mary T | Director | A | 39,800 | $0.00 | $0.00 |
| Jun 4, 2026 | Szela Mary T | Director | A | 10,100 | $0.00 | $0.00 |
| Jun 4, 2026 | Pangalos Menelas N | Director | A | 10,100 | $0.00 | $0.00 |
| Jun 4, 2026 | Pangalos Menelas N | Director | A | 39,800 | $0.00 | $0.00 |
| Jun 4, 2026 | VAN HOUTEN FRANS | Director | A | 39,800 | $0.00 | $0.00 |
| Jun 4, 2026 | VAN HOUTEN FRANS | Director | A | 10,100 | $0.00 | $0.00 |
| Jun 4, 2026 | Sirosh Joseph | Director | A | 39,800 | $0.00 | $0.00 |
| Jun 4, 2026 | Sirosh Joseph | Director | A | 10,100 | $0.00 | $0.00 |
| Jun 4, 2026 | Rabinovitsj Daniel A | Director | A | 39,800 | $0.00 | $0.00 |
| Jun 4, 2026 | Rabinovitsj Daniel A | Director | A | 10,100 | $0.00 | $0.00 |
| May 31, 2026 | Jonasson Zachariah | CFO / CBO | F | 8,319 | $6.75 | $56.2K |
| May 13, 2026 | Pangalos Menelas N | Director | BUY | 37,453 | $5.36 | $200.7K |
| Mar 12, 2026 | Busch Andreas | Chief Innovation Officer | BUY | 100,000 | $2.29 | $229.0K |
| Mar 3, 2026 | Bedrick Todd | SVP, CAO | F | 5,282 | $2.80 | $14.8K |
| Mar 3, 2026 | McClain Sean | Chief Executive Officer | F | 25,316 | $2.80 | $70.9K |
| Mar 3, 2026 | Walker Shelby J. | Chief Legal Officer | F | 9,825 | $2.80 | $27.5K |
| Mar 3, 2026 | Bedrick Todd | SVP, CAO | F | 5,282 | $2.80 | $14.8K |
| Mar 3, 2026 | Jonasson Zachariah | CFO / CBO | F | 10,848 | $2.80 | $30.4K |
| Mar 3, 2026 | Jonasson Zachariah | CFO / CBO | F | 10,848 | $2.80 | $30.4K |
| Mar 3, 2026 | Walker Shelby J. | Chief Legal Officer | F | 9,825 | $2.80 | $27.5K |
| Mar 2, 2026 | Walker Shelby J. | Chief Legal Officer | A | 90,300 | $0.00 | $0.00 |
| Mar 2, 2026 | Walker Shelby J. | Chief Legal Officer | A | 356,300 | $0.00 | $0.00 |
| Mar 2, 2026 | Jonasson Zachariah | CFO / CBO | A | 135,400 | $0.00 | $0.00 |
| Mar 2, 2026 | Bedrick Todd | SVP, CAO | A | 195,900 | $0.00 | $0.00 |
| Mar 2, 2026 | McClain Sean | Chief Executive Officer | A | 406,200 | $0.00 | $0.00 |
| Mar 2, 2026 | McClain Sean | Chief Executive Officer | A | 1,603,200 | $0.00 | $0.00 |
| Mar 2, 2026 | Walker Shelby J. | Chief Legal Officer | A | 356,300 | $0.00 | $0.00 |
| Mar 2, 2026 | Bedrick Todd | SVP, CAO | A | 49,600 | $0.00 | $0.00 |
| Mar 2, 2026 | Bedrick Todd | SVP, CAO | A | 195,900 | $0.00 | $0.00 |
| Mar 2, 2026 | Jonasson Zachariah | CFO / CBO | A | 135,400 | $0.00 | $0.00 |
| Mar 2, 2026 | Pangalos Menelas N | Director | A | 5,800 | $0.00 | $0.00 |
| Mar 2, 2026 | Pangalos Menelas N | Director | A | 22,800 | $0.00 | $0.00 |
| Mar 2, 2026 | Walker Shelby J. | Chief Legal Officer | A | 90,300 | $0.00 | $0.00 |
| Mar 2, 2026 | Jonasson Zachariah | CFO / CBO | A | 534,400 | $0.00 | $0.00 |
| Mar 2, 2026 | Bedrick Todd | SVP, CAO | A | 49,600 | $0.00 | $0.00 |
| Mar 2, 2026 | Jonasson Zachariah | CFO / CBO | A | 534,400 | $0.00 | $0.00 |
| Feb 27, 2026 | Pangalos Menelas N | Director | BUY | 75,095 | $2.74 | $205.8K |
| Feb 23, 2026 | McClain Sean | Chief Executive Officer | M | 396,399 | $1.21 | $479.6K |
| Feb 23, 2026 | McClain Sean | Chief Executive Officer | M | 396,399 | $0.00 | $0.00 |
| Feb 3, 2026 | Busch Andreas | Chief Innovation Officer | F | 1,469 | $2.99 | $4.4K |
| Feb 2, 2026 | Jonasson Zachariah | CFO / CBO | F | 17,496 | $2.99 | $52.3K |
| Feb 2, 2026 | McClain Sean | Chief Executive Officer | F | 26,761 | $2.99 | $80.0K |
| Feb 2, 2026 | Jonasson Zachariah | CFO / CBO | SELL | 17,496 | $2.99 | $52.3K |
| Feb 2, 2026 | McClain Sean | Chief Executive Officer | SELL | 26,761 | $2.99 | $80.0K |
| Feb 2, 2026 | Bedrick Todd | SVP, CAO | F | 3,659 | $2.99 | $10.9K |
| Jan 28, 2026 | Bedrick Todd | SVP, CAO | A | 59,400 | $0.00 | $0.00 |
| Jan 28, 2026 | Bedrick Todd | SVP, CAO | A | 15,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.5/10.
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 4 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.11 mean target
+33.4% upside
Strong Buy (1.36)
$4.10 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $6.83 |
| Target Low | $4.10 |
| Target Mean | $9.11 |
| Target Median | $9.50 |
| Target High | $12.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.36) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.22 | $-0.16 | 17.2% | +2.5% | 2↑ 1↓ | $0.0B | 70.1% | 9 |
| Next Q 2026-09-30 |
$-0.20 | $-0.23 | $-0.14 | -2.1% | -4.0% | 1↑ 2↓ | $0.0B | 180.9% | 9 |
| Current FY 2026-12-31 |
$-0.77 | $-0.87 | $-0.59 | 12.2% | +3.6% | 2↑ 1↓ | $0.0B | 98.7% | 11 |
| Next FY 2027-12-31 |
$-0.64 | $-0.87 | $-0.23 | 16.6% | -2.8% | 3↑ 1↓ | $0.0B | 196.4% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.199 | |
| 7d ago | $-0.200 | +0.001 |
| 30d ago | $-0.204 | +0.005 |
| 60d ago | $-0.204 | +0.005 |
| 90d ago | $-0.168 | -0.031 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | INITIATE | — | Outperform |
| May 28, 2026 | BTIG | INITIATE | — | Buy |
| May 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 25, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 18, 2026 | Needham | REITERATE | Buy | Buy |
| Dec 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 10 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 10 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 3 | 10 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 3 | 10 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 3 | 10 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$ABSI getting ready for take off
▲ 1
💬 0
⚡ 0.5
Jun 8, 2026
short_volume
Short Volume: ABSI — 63.0% short (0.8M / 1.3M)
Short: 806,968 | Exempt: 40,903 | TRF Vol: 1,280,288 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ABSI — 56.1% short (2.4M / 4.3M)
Short: 2,393,810 | Exempt: 30,176 | TRF Vol: 4,265,564 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: ABSI — 67.7% short (0.5M / 0.8M)
Short: 533,008 | Exempt: 773 | TRF Vol: 787,645 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: ABSI — 55.1% short (0.5M / 0.9M)
Short: 501,465 | Exempt: 2,236 | TRF Vol: 909,530 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: ABSI — 55.7% short (1.2M / 2.1M)
Short: 1,167,854 | Exempt: 8,732 | TRF Vol: 2,094,900 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
ABSI Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_interest
FTD: ABSI — 148,715 shares ($0.9M) failed to deliver
Settlement: 20260507, Price: $5.95, FTD Value: $884,854.25, ABSCI CORP
May 5, 2026
other
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceuti
Apr 23, 2026
earnings
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
<p align="justify">VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceu
Apr 8, 2026
other
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
<p align="justify">VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceu
Apr 2, 2026
short_interest
FTD: ABSI — 169,841 shares ($0.5M) failed to deliver
Settlement: 20260402, Price: $3.15, FTD Value: $534,999.15, ABSCI CORP
Mar 26, 2026
short_volume
Short Volume: ABSI — 57.9% short (0.8M / 1.3M)
Short: 760,855 | Exempt: 600 | TRF Vol: 1,314,320 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
earnings
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
<p align="center"><em>Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging
Mar 24, 2026
earnings_calendar
ABSI Q4 2025 Earnings After Market Close — 2026-03-24
Mar 18, 2026
short_interest
FTD: ABSI — 237,108 shares ($0.7M) failed to deliver
Settlement: 20260318, Price: $3.03, FTD Value: $718,437.24, ABSCI CORP